RxDoctor Payments DataLook up a doctor →

Amy Lacouture

Psychiatric/Mental Health · Baton Rouge, LANPI 1841617594

Payments from drug & device makers

$662,790in general payments, 2019–2025

Across 948 payments — averaging $699.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$635K
  • Alkermes, Inc.$27K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Axsome Therapeutics, Inc.$139
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$18
  • Teva Pharmaceuticals USA, Inc.$17
  • plus $12 from 1 others

What the payments were for

  • Consulting fees$77,55412%
  • Speaking & faculty fees$441,84467%
  • Travel & lodging$126,40419%
  • Food & beverage$16,9613%
  • Education$270%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$662,790 in reported general payments places this provider in the 95th percentile of 615 psychiatric/mental health providers in Louisiana.

See all psychiatric/mental health providers in Louisiana

Medicare billing

Part B allowed, 2024
$3,718
Medicare patients
19
Services billed
63

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate47$379,120
Invega SustennaPaliperidone Palmitate82$280,934
AristadaAripiprazole Lauroxil53$184,018
VraylarCariprazine Hcl61$88,114
TrintellixVortioxetine Hydrobromide45$22,165
LybalviOlanzapine/Samidorphan Malate14$20,523
Carbamazepine ErCarbamazepine25$1,992
Haloperidol Decanoate29$1,813
Haloperidol71$1,670
Quetiapine Fumarate101$1,283
Atomoxetine Hcl12$1,085
Hydroxyzine Pamoate98$877
Olanzapine31$814
Chlorpromazine Hcl12$731
Doxepin Hcl16$477

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$634,714$379,12047 claims
Johnson & JohnsonInvega Sustenna$12$280,93482 claims
Alkermes, Inc.Aristada, Lybalvi$26,886$204,54167 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 615 psychiatric/mental health providers in Louisiana.

Other psychiatric/mental health in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →